Please login to the form below

Not currently logged in


This page shows the latest Mitsubishi news and features for those working in and with pharma, biotech and healthcare.

GSK files anaemia drug daprodustat in Japan, its first market

GSK files anaemia drug daprodustat in Japan, its first market

class called vadadustat in late-stage clinical testing that is licensed to Mitsubishi Tanabe Pharma in some Asian markets including Japan.

Latest news

More from news
Approximately 1 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).

  • Deal Watch - May 2017 Deal Watch - May 2017

    It is not known why in December 2015 the territorial rights granted to Mitsubishi for vadadustat for treatment of anaemia, were limited to Japan, SE Asia and India.

  • Japanese pharma pulls no punches with post-Brexit UK Japanese pharma pulls no punches with post-Brexit UK

    The level of investment on the pharmaceutical side is considerable. The Japanese Pharmaceutical Group (JPG), an association of nine drugmakers - Astellas, Chugai, Daiichi-Sankyo, Eisai, Kowa, Mitsubishi Tanabe, Otsuka, Shionogi and

  • Deal Watch November 2016 Deal Watch November 2016

    generic company and distributor. acquisition - company. 462. Kolon Life Science | TissueGene / Mitsubishi.

  • Deal Watch October 2016 Deal Watch October 2016

    $203m. Mitsubishi Tanabe (JP) / Sept 15. Biogen (US). amiselimod / multiple sclerosis.

More from intelligence
Approximately 0 fully matching, plus 16 partially matching documents found.

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Time to talk about health inequalities
Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...